MDS-482 Impact of magrolimab in combination with azacitidine on red blood cells (RBCs) in patients with higher-risk myelodysplastic syndromes (HR MDS)
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Conference item |
| Language: | English |
| Published: |
Elsevier
2022
|
| _version_ | 1797110911417188352 |
|---|---|
| author | Chen, J Johnson, L McKenna, K Choi, T Duan, J Feng, D Tsai, J Garcia-Martin, N Sompalli, K Maute, R Vyas, P Majeti, R Takimoto, C Liu, J Ramsingh, G Chao, M Volkmer, J-P Weissman, I |
| author_facet | Chen, J Johnson, L McKenna, K Choi, T Duan, J Feng, D Tsai, J Garcia-Martin, N Sompalli, K Maute, R Vyas, P Majeti, R Takimoto, C Liu, J Ramsingh, G Chao, M Volkmer, J-P Weissman, I |
| author_sort | Chen, J |
| collection | OXFORD |
| description | |
| first_indexed | 2024-03-07T08:01:23Z |
| format | Conference item |
| id | oxford-uuid:fbddb2d5-8b84-4e66-9845-372d86fac7f5 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T08:01:23Z |
| publishDate | 2022 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:fbddb2d5-8b84-4e66-9845-372d86fac7f52023-09-21T08:37:31ZMDS-482 Impact of magrolimab in combination with azacitidine on red blood cells (RBCs) in patients with higher-risk myelodysplastic syndromes (HR MDS)Conference itemhttp://purl.org/coar/resource_type/c_c94fuuid:fbddb2d5-8b84-4e66-9845-372d86fac7f5EnglishSymplectic ElementsElsevier2022Chen, JJohnson, LMcKenna, KChoi, TDuan, JFeng, DTsai, JGarcia-Martin, NSompalli, KMaute, RVyas, PMajeti, RTakimoto, CLiu, JRamsingh, GChao, MVolkmer, J-PWeissman, I |
| spellingShingle | Chen, J Johnson, L McKenna, K Choi, T Duan, J Feng, D Tsai, J Garcia-Martin, N Sompalli, K Maute, R Vyas, P Majeti, R Takimoto, C Liu, J Ramsingh, G Chao, M Volkmer, J-P Weissman, I MDS-482 Impact of magrolimab in combination with azacitidine on red blood cells (RBCs) in patients with higher-risk myelodysplastic syndromes (HR MDS) |
| title | MDS-482 Impact of magrolimab in combination with azacitidine on red blood cells (RBCs) in patients with higher-risk myelodysplastic syndromes (HR MDS) |
| title_full | MDS-482 Impact of magrolimab in combination with azacitidine on red blood cells (RBCs) in patients with higher-risk myelodysplastic syndromes (HR MDS) |
| title_fullStr | MDS-482 Impact of magrolimab in combination with azacitidine on red blood cells (RBCs) in patients with higher-risk myelodysplastic syndromes (HR MDS) |
| title_full_unstemmed | MDS-482 Impact of magrolimab in combination with azacitidine on red blood cells (RBCs) in patients with higher-risk myelodysplastic syndromes (HR MDS) |
| title_short | MDS-482 Impact of magrolimab in combination with azacitidine on red blood cells (RBCs) in patients with higher-risk myelodysplastic syndromes (HR MDS) |
| title_sort | mds 482 impact of magrolimab in combination with azacitidine on red blood cells rbcs in patients with higher risk myelodysplastic syndromes hr mds |
| work_keys_str_mv | AT chenj mds482impactofmagrolimabincombinationwithazacitidineonredbloodcellsrbcsinpatientswithhigherriskmyelodysplasticsyndromeshrmds AT johnsonl mds482impactofmagrolimabincombinationwithazacitidineonredbloodcellsrbcsinpatientswithhigherriskmyelodysplasticsyndromeshrmds AT mckennak mds482impactofmagrolimabincombinationwithazacitidineonredbloodcellsrbcsinpatientswithhigherriskmyelodysplasticsyndromeshrmds AT choit mds482impactofmagrolimabincombinationwithazacitidineonredbloodcellsrbcsinpatientswithhigherriskmyelodysplasticsyndromeshrmds AT duanj mds482impactofmagrolimabincombinationwithazacitidineonredbloodcellsrbcsinpatientswithhigherriskmyelodysplasticsyndromeshrmds AT fengd mds482impactofmagrolimabincombinationwithazacitidineonredbloodcellsrbcsinpatientswithhigherriskmyelodysplasticsyndromeshrmds AT tsaij mds482impactofmagrolimabincombinationwithazacitidineonredbloodcellsrbcsinpatientswithhigherriskmyelodysplasticsyndromeshrmds AT garciamartinn mds482impactofmagrolimabincombinationwithazacitidineonredbloodcellsrbcsinpatientswithhigherriskmyelodysplasticsyndromeshrmds AT sompallik mds482impactofmagrolimabincombinationwithazacitidineonredbloodcellsrbcsinpatientswithhigherriskmyelodysplasticsyndromeshrmds AT mauter mds482impactofmagrolimabincombinationwithazacitidineonredbloodcellsrbcsinpatientswithhigherriskmyelodysplasticsyndromeshrmds AT vyasp mds482impactofmagrolimabincombinationwithazacitidineonredbloodcellsrbcsinpatientswithhigherriskmyelodysplasticsyndromeshrmds AT majetir mds482impactofmagrolimabincombinationwithazacitidineonredbloodcellsrbcsinpatientswithhigherriskmyelodysplasticsyndromeshrmds AT takimotoc mds482impactofmagrolimabincombinationwithazacitidineonredbloodcellsrbcsinpatientswithhigherriskmyelodysplasticsyndromeshrmds AT liuj mds482impactofmagrolimabincombinationwithazacitidineonredbloodcellsrbcsinpatientswithhigherriskmyelodysplasticsyndromeshrmds AT ramsinghg mds482impactofmagrolimabincombinationwithazacitidineonredbloodcellsrbcsinpatientswithhigherriskmyelodysplasticsyndromeshrmds AT chaom mds482impactofmagrolimabincombinationwithazacitidineonredbloodcellsrbcsinpatientswithhigherriskmyelodysplasticsyndromeshrmds AT volkmerjp mds482impactofmagrolimabincombinationwithazacitidineonredbloodcellsrbcsinpatientswithhigherriskmyelodysplasticsyndromeshrmds AT weissmani mds482impactofmagrolimabincombinationwithazacitidineonredbloodcellsrbcsinpatientswithhigherriskmyelodysplasticsyndromeshrmds |